GeneFerm Biotechnology Co

GeneFerm Biotechnology Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of GeneFerm Biotechnology Co (1796.TWO) as of Oct 20, 2026 is 26.61. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -132.83 — a change of -120.03% (higher).

EV/FCF

26.61

YoY

-120.03%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of GeneFerm Biotechnology Co is 2025 26.61 . EV/FCF (Enterprise Value to Free Cash Flow) of GeneFerm Biotechnology Co was 2024 -132.83 . It decreases by -120.03% higher compared to the previous year.

The GeneFerm Biotechnology Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
139.04 TWD
Jan 1, 2019
-58.74 TWD
Jan 1, 2020
-76.35 TWD
Jan 1, 2021
-52.11 TWD
Jan 1, 2022
-12.39 TWD
Jan 1, 2023
15.52 TWD
Jan 1, 2024
-132.83 TWD
Jan 1, 2025
26.61 TWD
The GeneFerm Biotechnology Co EV/FCF history
YEAREV/FCFYoY
26.61-120.03%
-132.83-955.73%
15.52-225.30%
-12.39-76.22%
-52.11-31.75%
-76.35+29.98%
-58.74-142.25%
139.04-55.49%
312.38+102.06%
154.60+235.99%
46.01-91.27%
526.94—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneFerm Biotechnology Co Stock analysis

What does GeneFerm Biotechnology Co do? GeneFerm Biotechnology Co., Ltd. generates revenue through the manufacture and sale of health food and supplement products, including fermented products, medicinal mushrooms, lactic acid bacteria products, and fruit and vegetable fermented concentrate products. The company also offers related manufacturing services, health food design, and research and development services. Its primary customers are consumers seeking health-focused dietary supplements, with a focus on fermented and natural health food solutions. The firm targets health-conscious individuals and wellness-oriented markets through its product portfolio. The business model relies on direct sales of its branded health food products, leveraging the growing demand for natural and fermented dietary supplements. The company's R&D services support product innovation, while manufacturing services cater to partners requiring specialized production capabilities. Health food design services further enhance its offerings for clients in the wellness industry. GeneFerm's revenue streams are derived from both product sales and service-based offerings, with a strong emphasis on fermented health food solutions. The company's focus on medicinal mushrooms and lactic acid bacteria products differentiates its market position, appealing to consumers interested in natural health remedies and probiotic benefits. GeneFerm Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneFerm Biotechnology Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of GeneFerm Biotechnology Co is 26.61 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of GeneFerm Biotechnology Co changed from -132.83 to 26.61, representing a -120.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) GeneFerm Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s GeneFerm Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — GeneFerm Biotechnology Co

All Key Metrics — GeneFerm Biotechnology Co